Contact lenses

Allergan announces positive phase 3 topline results for investigational eye drop for the treatment of presbyopia

Allergan announced the phase 3 GEMINI 1 and 2 clinical trials evaluating the efficacy, safety, and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of symptoms associated with presbyopia, met their primary efficacy endpoint.

In GEMINI 1, the primary endpoint was met with a statistically significant greater proportion of participants treated with AGN-190584 who gained 3 lines or more in mesopic (in low light), high contrast, binocular Distance Corrected Near Visual Acuity (DCNVA) at Day 30, Hour 3 versus the vehicle (placebo). In…

Read More

featured stories

View Conference Coverage

Take a look at some of our conference coverage, visit our roundup section.

Conference Roundup

  1. Aug 10, 2018

Plain Talk About the Consequences of Poor Contact Lens Care

Contact lens acute red eye may be caused by several factors, including, contact lens over wear, sleeping in contact lenses, or poor hygiene, noted Tami Hagemeyer, ABOC, lead optician at Premier Vision Group in Bowling Green, OH, during the American Optometric Association’s 2018 annual meeting in…

View All

Journal Scan

  1. Jan 10, 2020

Soft Contact Lens-induced Dry Eye Linked to Tear Dynamics Only While Wearing Lenses

Soft contact lens-related dry eye was associated with tear dynamics while wearing soft contact lenses but not after they were removed, according to a study published by Current Eye Research.

The prospective study analyzed…

View All

Trending Topics

  1. Oct 29, 2020

Allergan announces positive phase 3 topline results for investigational eye drop for the treatment of presbyopia

Allergan announced the phase 3 GEMINI 1 and 2 clinical trials evaluating the efficacy, safety, and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of symptoms associated with presbyopia, met their primary efficacy endpoint.

In GEMINI 1…

View All

Resources